Summit Therapeutics 1 article

The scientific profile of Summit Therapeutics combines dual immune checkpoint and angiogenesis targeting with solid tumor antibody therapy, placing the company in targeted biologic drug development. The company links lung cancer immunotherapy with bispecific monoclonal antibody therapeutics; tumor immune microenvironment modulation shows how antibody format or binding architecture is translated into a biological effect. For entity matching, binding format and drug molecule are separate from the organization; Summit Therapeutics is also associated with antiangiogenic immunotherapy.